Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sasanlimab Maintenance in Bladder-Sparing MIBC
NCT06623162Phase 2Not yet recruiting
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sasanlimab in muscle-invasive bladder cancer (MIBC), sponsored by Fundación de Investigación HM Hospitales. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
sasanlimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06623162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623162.